Wed, Nov 27, 2024
Volume 4, Issue 1 (1-2016)
J. Pediatr. Rev 2016, 4(1): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Golpour M, Ghaffari J. Hyperimmunoglobulin-D Syndrome in Children: A Review Article . J. Pediatr. Rev 2016; 4 (1)
URL: http://jpr.mazums.ac.ir/article-1-119-en.html
URL: http://jpr.mazums.ac.ir/article-1-119-en.html
1- Associated Professor of Dermatology, Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
2- Professor of Allergy and Clinical Immunology, Infectious Disease Research Center with Focus on Nosocomial Infection, Mazandaran University of Medical Sciences, Sari, IR Iran ,javadneg@yahoo.com
2- Professor of Allergy and Clinical Immunology, Infectious Disease Research Center with Focus on Nosocomial Infection, Mazandaran University of Medical Sciences, Sari, IR Iran ,
Abstract: (4458 Views)
Hyperimmunoglobulin-D syndrome (HIDS) is a rare, autosomal recessively inherited autoinflammatory disease caused by mutations in the mevalonate kinase gene. HIDS usually starts in infancy with recurrent fever episodes lasting three to seven days and recurring every three to six weeks, with only partial symptom decrease in adulthood. Fever is typically accompanied by abdominal pain, vomiting, diarrhea and cervical lymphadenopathy, and sometimes by skin and joint symptoms. Blood leukocytes and serum C-reactive protein (CRP) are elevated during the episode, and in addition, high levels of interleukine-1 (IL-1), IL-6 and tumor necrosis factor (TNF) and respective soluble receptors are measured. Currently, there is no established treatment for HIDS. So far, four children have been successfully treated by TNF-alpha inhibitor (etanercept) and three children with IL-1 receptor antagonist (anakinra). The current study is a narrative review about the updates of HIDS.
Type of Study: Narrative Review |
Received: 2015/11/3 | Accepted: 2016/01/21 | Published: 2016/01/26
Received: 2015/11/3 | Accepted: 2016/01/21 | Published: 2016/01/26
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC),
which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
